Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mol Pharm ; 17(7): 2354-2369, 2020 07 06.
Artículo en Inglés | MEDLINE | ID: mdl-32352791

RESUMEN

Gram-negative bacteria possess numerous defenses against antibiotics, due to the intrinsic permeability barrier of their outer membrane (OM), explaining the recalcitrance of some common and life-threatening infections. We report the formulation of a new drug, PPA148, which shows promising activity against all Gram-negative bacteria included in the ESKAPEE pathogens. PPA148 was solubilized by inclusion complexation with cyclodextrin followed by encapsulation in liposomes. The complex and liposomal formulation presented increased activity against E. coli compared to the pure drug when assessed with the Kirby Bauer assay. The novel formulation containing 1 µg PPA148 reached similar efficacy levels equivalent to those of 30 µg of pure rifampicin. A range of biophysical techniques was used to explore the mechanism of drug uptake. Langmuir trough (LT) and neutron reflectivity (NR) techniques were employed to monitor the interactions between the drug and the formulation with model membranes. We found evidence for liposome fusion with the model Gram-negative outer membrane and for cyclodextrins acting as inner membrane (IM) permeation enhancers without presenting intrinsic antimicrobial activity. An antibiotic-in-cyclodextrin-in-liposomes (ACL) formulation was developed, which targets both the bacterial OM and IM, and offers promise as a means to breach the Gram-negative cell envelope.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Membrana Externa Bacteriana/metabolismo , Benzodiazepinas/administración & dosificación , Benzodiazepinas/farmacocinética , Ciclodextrinas/química , Composición de Medicamentos/métodos , Sistemas de Liberación de Medicamentos/métodos , Escherichia coli/metabolismo , Pirroles/administración & dosificación , Pirroles/farmacocinética , Antibacterianos/química , Membrana Externa Bacteriana/efectos de los fármacos , Benzodiazepinas/química , Permeabilidad de la Membrana Celular/efectos de los fármacos , Farmacorresistencia Bacteriana , Escherichia coli/efectos de los fármacos , Membrana Dobles de Lípidos/metabolismo , Liposomas , Fusión de Membrana , Modelos Biológicos , Pirroles/química , Rifampin/farmacología , Solubilidad
2.
Langmuir ; 34(21): 6125-6137, 2018 05 29.
Artículo en Inglés | MEDLINE | ID: mdl-29726688

RESUMEN

π-Conjugated polymer nanoparticles (CPNs) are under investigation as photoluminescent agents for diagnostics and bioimaging. To determine whether the choice of surfactant can improve CPN properties and prevent protein adsorption, five nonionic polyethylene glycol alkyl ether surfactants were used to produce CPNs from three representative π-conjugated polymers. The surfactant structure did not influence size or yield, which was dependent on the nature of the conjugated polymer. Hydrophobic interaction chromatography, contact angle, quartz crystal microbalance, and neutron reflectivity studies were used to assess the affinity of the surfactant to the conjugated polymer surface and indicated that all surfactants were displaced by the addition of a model serum protein. In summary, CPN preparation methods which rely on surface coating of a conjugated polymer core with amphiphilic surfactants may produce systems with good yields and colloidal stability in vitro, but may be susceptible to significant surface alterations in physiological fluids.


Asunto(s)
Luminiscencia , Nanopartículas/química , Polímeros/química , Tensoactivos/química , Luz , Unión Proteica , Surfactantes Pulmonares , Propiedades de Superficie
3.
Biochemistry ; 56(8): 1163-1174, 2017 02 28.
Artículo en Inglés | MEDLINE | ID: mdl-28156093

RESUMEN

HT61 is a quinoline-derived antimicrobial, which exhibits bactericidal potency against both multiplying and quiescent methicillin resistant and sensitive Staphylococcus aureus, and has been proposed as an adjunct for other antimicrobials to extend their usefulness in the face of increasing antimicrobial resistance. In this study, we have examined HT61's effect on the permeability of S. aureus membranes and whether this putative activity can be attributed to an interaction with lipid bilayers. Using membrane potential and ATP release assays, we have shown that HT61 disrupts the membrane enough to result in depolarization of the membrane and release of intercellular constituents at concentrations above and below the minimum inhibitory concentration of the drug. Utilizing both monolayer subphase injection and neutron reflectometry, we have shown that increasing the anionic lipid content of the membrane leads to a more marked effect of the drug. In bilayers containing 25 mol % phosphatidylglycerol, neutron reflectometry data suggest that exposure to HT61 increases the level of solvent in the hydrophobic region of the membrane, which is indicative of gross structural damage. Increasing the proportion of PG elicits a concomitant level of membrane damage, resulting in almost total destruction when 75 mol % phosphatidylglycerol is present. We therefore propose that HT61's primary action is directed toward the cytoplasmic membrane of Gram-positive bacteria.


Asunto(s)
Antiinfecciosos/química , Antiinfecciosos/farmacología , Membrana Celular/efectos de los fármacos , Quinolinas/química , Quinolinas/farmacología , Antiinfecciosos/metabolismo , Membrana Celular/metabolismo , Membrana Dobles de Lípidos/metabolismo , Potenciales de la Membrana/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Quinolinas/metabolismo , Staphylococcus aureus/citología , Staphylococcus aureus/efectos de los fármacos
4.
Eur J Pharm Biopharm ; 146: 64-72, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31756380

RESUMEN

Proteases play a vital role in lung health and are critically important to the metabolic clearance of inhaled protein-based therapeutics after inhalation. Surprisingly little is known about lung fluid protease composition and there is a consequent lack of biorelevant experimental models, which limits research and development in the burgeoning field of inhaled biologics. The aim of this study was to quantify proteases in human lung fluid and to use this data to design novel in vitro experimental models of lung lining fluid possessing biorelevant lung protease activity for use in biopharmaceutical stability studies. As a proof of concept, these novel models were used to investigate the effect of proteolytic activity on the stability of albumin nanoparticles, a biologic nanoparticle formulation widely investigated as a pulmonary drug delivery system. Bronchoalveolar lavage fluid was collected from healthy human volunteers and proteomic analysis was used to quantify the predominant proteases. Based on these data, four new lung protease models were constructed based on: (i) trypsin as a sole protease, (ii) dipeptidyl peptidase IV, cathepsin D, cathepsin H, and angiotensin converting enzyme in ratio and concentration to mimic the protease concentration in healthy lungs. Neutrophil elastase was used to model protease activity in inflammation. Albumin nanoparticles of 100 nm diameter remained intact over 48 h in phosphate buffered saline, but were degraded more rapidly in trypsin (50% reduction in 10 min) compared to the healthy lung protease model (50% reduction in 150 min). The addition of neutrophil elastase to the healthy lung protease model resulted in a similar, but more variable degradation profile. Nanoparticle degradation was associated with concomitant appearance of small fragments and aggregates. In conclusion, we have characterised the protease concentration in the lungs of healthy humans, designed models of lung protease activity and demonstrated their utility in studying albumin nanoparticle degradation. These methods and models have wide application to study the influence of proteases in lung disease, expression of proteases in respiratory cell culture models, stability of peptide and protein-based drugs and inhaled drug delivery systems.


Asunto(s)
Productos Biológicos/farmacocinética , Sistemas de Liberación de Medicamentos , Modelos Biológicos , Péptido Hidrolasas/metabolismo , Proteómica/métodos , Administración por Inhalación , Adulto , Productos Biológicos/administración & dosificación , Líquido del Lavado Bronquioalveolar/química , Estabilidad de Medicamentos , Femenino , Voluntarios Sanos , Humanos , Pulmón/enzimología , Pulmón/inmunología , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/inmunología , Masculino , Nanopartículas/química , Nanopartículas/metabolismo , Tamaño de la Partícula , Péptido Hidrolasas/análisis , Proteolisis , Albúmina Sérica Bovina/administración & dosificación , Albúmina Sérica Bovina/farmacocinética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA